Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
T-cell prolymphocytic leukemia (T-PLL) is an aggressive T-cell leukemia.
Leukemic T-cells are found in the peripheral blood, bone marrow, lymph nodes, spleen, liver and sometimes skin.
Cutaneous involvement consists of perivascular or more diffuse dermal infiltrations without epidermotropism.
The spleen histology shows dense red pulp infiltration which invades the spleen capsule, blood vessels and atrophied white pulp.
There is diffuse lymph node involvement and tends to predominate in the paracortical areas, sometimes with sparing of follicles. Prominent high-endothelial venules may be numerous and are often infiltrated by neoplastic cells.
Leukemic T-cells are found in the peripheral blood, bone marrow, lymph nodes, spleen, liver and sometimes skin.
Cutaneous involvement consists of perivascular or more diffuse dermal infiltrations without epidermotropism.
The spleen histology shows dense red pulp infiltration which invades the spleen capsule, blood vessels and atrophied white pulp.
There is diffuse lymph node involvement and tends to predominate in the paracortical areas, sometimes with sparing of follicles. Prominent high-endothelial venules may be numerous and are often infiltrated by neoplastic cells.
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Grade
Not Applicable
Module Rule
None
Alternate Names
Definition
T-cell prolymphocytic leukemia (T-PLL) is an aggressive T-cell leukemia characterized by the proliferation of small to medium-sized prolymphocytes with a mature post-thymic T-cell phenotype, involving the peripheral blood, bone marrow, lymph nodes, liver, spleen, and skin.
Definitive Diagnostic Methods
Bone marrow biopsy
Genetic testing
Immunophenotyping
Peripheral blood smear
Genetics Data
Immunophenotyping
CD1a- (no expression/negative)
CD2+ (expression/positive)
CD3+ (expression/positive)
CD4+ (expression/positive)
CD5+ (expression/positive)
CD7+ (expression/positive)
CD8- (no expression/negative)
CD52 usually depressed at high density, can be used as a target of therapy
TdT- (no expression/negative)
Treatments
Chemotherapy
Hematologic Transplant and/or Endocrine Procedures
Transformations to
There are no known transformations
Transformations from
There are no known transformations
Same Primaries
Corresponding ICD-9 Codes
204.8 Other lymphoid leukemia
Corresponding ICD-10 Codes
C91.3 Prolymphocytic Leukemia
Corresponding ICD-10-CM Codes (U.S. only)
C91.6 Prolymphocytic leukemia of T-cell type (effective October 01, 2015)
Signs and Symptoms
Anemia
Generalized lymphadenopathy
Hepatosplenomegaly
Skin infiltration (20% of patients)
Thrombocytopenia
Diagnostic Exams
Progression and Transformation
None
Epidemiology and Mortality
Age: 65 years median age (range 30-94)
Survival: aggressive course, median survival time 1 year
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Mature T- and NK-cell neoplasms
Pages: 346-347
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Mature T- and NK-cell neoplasms
Pages: 346-347
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577